

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

In re Entresto (Sacubitril/Valsartan) Patent Litigation

MDL No. 20-2930-RGA

NOVARTIS PHARMACEUTICALS
CORPORATION,

Plaintiff,

V.

C.A. No. 19-1979-RGA

TORRENT PHARMA INC., TORRENT
PHARMACEUTICALS LTD.,

Defendant.

NOVARTIS PHARMACEUTICALS
CORPORATION,

Plaintiff,

V.

C.A. No. 19-2021-RGA

ALEMBIC PHARMACEUTICALS
LIMITED, ALEMBIC GLOBAL
HOLDING SA, ALEMBIC
PHARMACEUTICALS, INC.,

Defendants.

NOVARTIS PHARMACEUTICALS
CORPORATION,

Plaintiff,

V.

C.A. No. 19-2053-RGA

HETERO USA INC., HETERO LABS LIMITED, HETERO LABS LIMITED UNIT III, MSN PHARMACEUTICALS INC., MSN LABORATORIES PRIVATE LIMITED, MSN LIFE SCIENCES PRIVATE LIMITED,

Defendants.

NOTICE OF APPEAL

Notice is hereby given that Plaintiff Novartis Pharmaceuticals Corporation appeals to the United States Court of Appeals for the Federal Circuit from the Judgment entered on July 21, 2023 in MDL No. 20-2930-RGA and Civil Actions Nos. 19-1979-RGA, 19-2021-RGA and 19-2053-RGA, and all other rulings, conclusions, determinations, findings, opinions and orders that were adverse to Novartis.

Date: July 24, 2023

McCARTER & ENGLISH, LLP

/s/ Daniel M. Silver

Daniel M. Silver (#4758)

Alexandra M. Joyce (#6423)

Renaissance Centre

405 N. King Street, 8th Floor

Wilmington, Delaware 19801

(302) 984-6300

dsilver@mccarter.com

ajoyce@mccarter.com

Attorneys for Plaintiff Novartis

Pharmaceuticals Corporation

OF COUNSEL:

Nicholas N. Kallas

Christina Schwarz

Christopher E. Loh

Jared L. Stringham

VENABLE LLP

151 West 42nd Street

New York, New York 10036

(212) 307-5500

nkallas@venable.com

cschwarz@venable.com

cloh@venable.com

jlstringham@venable.com